Dynavax Technologies Corp(DVAX) Finding the best opportunities to buy and sell stocks daily.

Sector:

Healthcare

Description:

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older. Its immuno-oncology portfolio includes development stage products, such as SD-101 and DV281. Dynavax Technologies Corporation has a research collaboration with Clover Biopharmaceuticals; the University of Queensland and the Coalition for Epidemic Preparedness; and Sinovac Biotech Ltd. for the development of a vaccine candidate to prevent coronavirus (COVID-19). Dynavax Technologies Corporation has partnership with the Coalition for Epidemic Preparedness Innovations (CEPI) to create a vaccine against COVID-19 infection; a collaboration with Valneva SE to initiate a vaccine program for the coronavirus, COVID-19; and collaboration with Medicago to develop a novel adjuvanted COVID 19 vaccine candidate. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was founded in 1996 and is headquartered in Emeryville, California.

Current Price

$8.88

RSI

22.777

Beta:

1.254274

February 25, 2021
32.1M
181.3M
-16.5M

84.957 %
3.128 %
57.920 %
21.605 %

$46,551,000
$35,219,000
$8,198,000
$327,000
$11,043,000
$4,050,000
32.176 %
329.605 %
2407.034 %
-3277.064 %
172.667 %

$-75,240,000
$-152,600,000
$-158,899,000
$-95,154,000
$-112,444,000
$-106,794,000
102.818 %
4.128 %
-40.117 %
18.171 %
-5.025 %

News

Press Releases

Notable Dates

All stock recommendations and comments are all opinions. Investors should be cautious about any and all stock recommendations and should consider the source of any advice on stock selection. Various factors, including personal ownership, may influence or factor into a stock analysis or opinion. All investors are advised to conduct their own independent research into individual stocks before making a purchase decision. In addition, investors are advised that past stock performance is not indicative of future price action.